This is a useful study in the role of CHI3L1 in Kupffer cells, the macrophages of the liver, showing that CHI3L1 alters glucose regulation in obesity. Specifically, Chi3l1 protects glucose-dependent ...

The liver fibrosis market is entering a transformative phase, driven by greater awareness, improved diagnostic ...

8.4 Hospital Pharmacies 8.5 Speciality Pharmacies 8.6 Other Pharmacies 9 Liver Fibrosis / NASH / MASH Drugs Market Analysis by Region 9.1 Key Findings 9.2 Regional Market Size Estimation and Forecast ...

Research and Markets Wed, Apr 9, 2025, 3:11 AM8 min read Company Logo Dublin, April 09, 2025 (GLOBE NEWSWIRE) -- The "Liver Fibrosis & NASH/MASH Drugs Market Report 2025-2035" has been added to ...

MASH clinical trials test treatments for metabolic dysfunction-associated steatohepatitis, focusing on reversing liver inflammation, fibrosis, and fat accumulation safely.

Company founder Becky Taub pointed out that Madrigal believes Rezdiffra “will change the treatment paradigm for NASH with moderate to advanced liver fibrosis, giving physicians a liver-directed ...

NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those ...

Among 931 participants, OCA demonstrated its potential with 22.4% achieving an improvement in fibrosis without NASH worsening, compared to only 9.6% on a placebo. Furthermore, 6.5% of those on OCA ...

Treatment of NLO with a DPR1 inhibitor, Mdivi-1 resulted in the improvement of morphology and the decreased expression of fibrosis-related markers, Col1a1 and Acta2. In addition, treatment of NASH ...

Findings showed that 26% and 30% of patients treated with resmetirom 80mg and 100mg, respectively, achieved NASH resolution with at least a 2-point reduction in NAS and no worsening of fibrosis ...

And just like that, we have a crowded race to be the first approved NASH treatment—a market that could grow to $108.4 Billion globally by 2030.